Get the Daily Brief
Latest Biotech News
China clears clinical long‑read sequencer; Swiss Rockets licenses CoolMPS
Berry Genomics received National Medical Products Administration Class III approval for PacBio’s Sequel II CNDx system — the first regulatory clearance for a clinical‑grade long‑read sequencer in...
SGLT2 class shows kidney benefits across populations — large analyses
A landmark nephrology analysis reinforced that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors deliver kidney and cardiovascular benefits across patients with differing glomerular filtration...
Single‑cell consolidation — Qiagen buys Parse as 10x revenue softens
Qiagen agreed to acquire single‑cell specialist Parse Biosciences for up to $280 million, signaling continued consolidation as large instrument companies absorb high‑throughput single‑cell...
Braveheart funding surge — VCs back new biotech trio
Braveheart Bio closed a major financing and surfaced in multiple venture updates as new biotech launches attracted investor capital. Braveheart secured $185 million to advance a cardiometabolic...
Onchilles advances ELANE program — $25M round to push N17350
Onchilles Pharma published a landmark study on the ELANE pathway and announced $25 million in financing to advance N17350, a cancer‑killing enzyme–based therapeutic, toward first‑in‑human studies....
Intellia CRISPR patient dies — Phase 3 ATTR studies halted
Intellia Therapeutics disclosed that a patient dosed with its in vivo CRISPR candidate nexiguran ziclumeran (nex‑z) has died following severe liver injury, and the company paused dosing across its...
FDA expands National Priority Vouchers — six more drugs added
The FDA added six more therapies to its Commissioner’s National Priority Voucher (CNPV) program, expanding a pilot designed to accelerate review of drugs deemed in the national interest. The...
Pfizer and Novo Nordisk spar over Metsera — price approaches $10B
Two of the industry’s biggest players pushed a high‑stakes auction for obesity biotech Metsera this week, with Pfizer emerging the reported winner after upping its offer and valuing the company at...
China clears PacBio long‑read sequencer — Illumina export ban lifted
Pacific Biosciences said China’s National Medical Products Administration approved Berry Genomics’ Sequel II CNDx system — the world’s first regulatory clearance for a clinical‑grade long‑read...
SGLT2 inhibitors show kidney benefit across GFR and albuminuria
Large new analyses presented at recent nephrology forums and published in JAMA report that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors provide kidney protection across a broad spectrum of...
MIT LNP cuts mRNA vaccine dose by 100x — new ionizable lipid
Researchers at MIT reported a next‑generation lipid nanoparticle (LNP) formulation that delivered an influenza mRNA vaccine at roughly 1/100th the dose required by current FDA‑approved LNP...
Qiagen buys Parse Biosciences — single‑cell tools consolidate
Qiagen agreed to acquire Seattle‑based Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell library and automation platform into a larger public company. Parse...
Lilly’s amylin eloralintide posts strong weight‑loss; Phase 3 planned
Eli Lilly reported Phase 2 results showing its amylin receptor agonist eloralintide produced substantial weight loss, with some arms showing mean reductions comparable to leading GLP‑1 therapy and...
FDA clears DARZALEX Faspro for high‑risk smoldering myeloma
Johnson & Johnson’s DARZALEX Faspro received FDA approval for treatment of adult patients with high‑risk smoldering multiple myeloma, offering the first approved therapy for this earlier disease...
Biohub merges AI and biology — EvolutionaryScale team joins new initiative
Mark Zuckerberg and Priscilla Chan announced a new Biohub initiative that integrates EvolutionaryScale’s AI team and aligns frontier compute with experimental biology to accelerate disease...
Intellia CRISPR trial: patient death prompts FDA clinical hold
Intellia reported that an elderly patient dosed with its in‑vivo CRISPR candidate nexiguran ziclumeran (nex‑z) died after hospitalization for severe liver injury, and the FDA placed a clinical...
FDA expands priority voucher list: six more therapies win fast-track
The FDA added six additional drugs to its Commissioner’s National Priority Voucher (CNPV) pilot, expanding a program designed to accelerate review timelines for therapies deemed in the national...
Metsera takeover fight: Pfizer tops Novo with $10 billion offer
Pfizer upped its offer and moved to acquire obesity biotech Metsera, outbidding Novo Nordisk in a high‑stakes auction that valued the startup at close to $10 billion, according to company...
MIT particles slash mRNA dose: 100‑fold potency gain reported
MIT researchers published preclinical results showing a new class of degradable cyclic amino ionizable lipids and particle formulations that delivered influenza mRNA at roughly 1/100th the dose of...
PacBio Sequel II CNDx cleared: China approves first clinical long‑read sequencer
PacBio and clinical partner Berry Genomics received Class III medical device registration from China’s National Medical Products Administration (NMPA) for the Sequel II CNDx system, marking the...